Dishman Carbogen Amcis has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Bavla facility, after successfully inspected by the USFDA in October 2018.
Thus, the company's facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.
Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.
